Magram has over 20 years of drug discovery and development experience. She was the founding chief scientific officer of Northern Biologics, a Toronto Canada based biotechnology company. Prior to Northern Biologics, she served as the site head for Pfizer's Centers for Therapeutic Innovation, New York.
Previously, Magram was vice president, immunology and inflammation research at Boehringer Ingelheim, overseeing a department committed to drug discovery to address unmet medical needs in autoimmune disease.
Prior to Boehringer Ingelheim, she was an associate director of G protein-coupled receptor drug discovery at OSI Pharmaceuticals. She also previously spent over five years at Hoffmann-La Roche focused on using model systems to understand the pathophysiology of disease and to identify new therapies.
Magram completed her postdoctoral training in the laboratory of Nobel Laureate J. Michael Bishop, M.D. at the University of California, San Francisco School of Medicine and obtained her Ph.D. in the laboratory of Franklin Costantini, Ph.D. in the Department of Genetics and Development at Columbia University Irving Medical Center.
Privately held Quentis Therapeutics is pursuing first-in-class endoplasmic reticulum stress response-targeted therapies to address serious diseases such as cancer.
The company is pioneering the use of ER stress response modulators to boost the immune system's ability to fight cancer and to help more cancer patients benefit from immunotherapy. Its lead program is a first-in-class, small molecule, IRE1α inhibitor.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial